What top creators are saying about Hims & Hers Health, Inc.(HIMS)

Presents an attractive entry point driven by strong top-line revenue growth, wearable development, and a distribution partnership role with Novo Nordisk for weight-loss drugs.

Fundamentally undervalued with an attractive Gross Profit over Revenue Growth ratio around 0.1, making it a compelling long-term opportunity despite interest rate-driven drawdowns.

An undervalued growth asset with upcoming catalysts including a full mobile application redesign and international platform integration.

Experiencing strong consumer demand by providing direct access to affordable GLP-1 weight-loss options and bypassing traditional insurance friction via recurring subscriptions.

Despite moving within a 20% volatility band, the valuation is considered way too cheap relative to underlying fundamentals, presenting an attractive entry point for long-term investors.

Highlighted through an on-chain MemeFi tokenized liquidity pair that gained public visibility following engagement from the company's CEO.

Tokenized trading volume remains too negligible relative to its $6.5 billion market cap to influence traditional equity price action or trigger short squeezes.

Tokenized stock traded up to $132 on weekend AMM pools due to severe liquidity imbalances, highlighting counterparty and redemption risks.

Capturing market share in high-demand categories like weight loss and GLP-1 access through end-to-end online visits and direct-to-door delivery.

On-chain paired token demand forces liquidity providers to mint new tokenized shares, translating into real 1:1 backed off-chain share purchases and increased retail search volume.

Recent 18% pullback offers long-term upside driven by an EV/GP/RG ratio of 0.1, a Rule of 40 score of 46, and strong positioning for 2026-2027 peptide distribution approvals.

Highlighted for extreme price dislocations and volatility caused by unbacked on-chain tokenized trading pools outside traditional market hours.

Represents a deep-value opportunity trading at a discounted 0.10 valuation multiple despite resilient underlying fundamentals.

Tokenized pairings with meme coins carry severe volatility and liquidity risks, with retail facing downside risk from inefficient on-chain arbitrage against the underlying equity.

Telehealth stock valued around $6 billion paired with the BONER meme coin in the stock-meme trend.

Referenced as the pairing narrative for the Boner meme token which reached $90M.

Tokenized synthetic weekend trading pairs deviate significantly from real-market closing prices, exposing retail liquidity providers to recurring Monday institutional arbitrage losses.

Noted as having a $6B market capitalization and used as a benchmark valuation comparison

Targeted by speculative MemeFi social trading tokens characterized by insider momentum and rapid liquidity shifts.

Mentioned as a $7 billion market cap stock connected to the BONER token narrative.

Tokenized shares are utilized as real-world asset pairings with meme coins on the Robinhood chain ecosystem.

Purchased as synthetic stock using trading transaction fees generated by satirical meme coin pairs.

Exhibiting strong market presence at a $6 billion market cap, driven by elevated internet search volume for peptides.

Tokenized HIMS stock paired with memecoins on AMMs is driving on-chain premium pricing and liquidity provisioning yields.

Subjected to indiscriminate growth stock selling pressure despite maintaining an organically growing, recession-resistant business detached from interest rate impacts.

Could benefit as companies openly embrace stock-backed meme communities; viewed as a highly convex trade at current prices where investors might regret not holding a small position in the coming weeks.

Subject to artificial equity supply constraints as tokenized shares are locked into on-chain meme coin liquidity pools.

Facilitating friction-free telehealth access to high-demand GLP-1 weight-loss medications, expanding recurring subscription revenue and customer base.

Closed at $28.84 on the NYSE but surged to around $39 (a 37% premium) in onchain tokenized trading due to limited inventory and a float squeeze.

Presents a long-term hyper-growth opportunity in digital health where current valuation does not fully reflect international expansion, GLP-1 distribution, or high-margin product rollouts, though investors should expect continued share price volatility.

Broad-market basket selling has disconnected the stock from its underlying business performance and low-risk balance sheet, creating a buying opportunity in a recession-resistant business.

Viewed as consistently undervalued with strong fundamentals, strong Rule of 40 score, and high-margin upside from GLP-1 drug expansion and future peptide approvals.

The 10% sell-off driven by recycled reports regarding customer returns is a market overreaction with minimal financial impact (~$75,000), offering a value buying opportunity at fundamentally cheap valuation levels.

Placed into Visa's acquirer monitoring program due to elevated subscription chargebacks and cancellations, compounded by high 30%-40% short interest.

Traded up 3.5% as broader healthcare and pharmaceutical names benefited from sector rotation.

Gained 13% as macro liquidity flows lifted high-growth risk-on assets; maintained as a top conviction holding.

Demonstrated significant positive momentum supported by broader inflows into the healthcare sector.

Short-term macro pressure is disconnecting the share price from solid fundamentals, creating a long-term growth opportunity in off-patent GLP-1 and peptide commercialization.

Strong Q2 results with 38% YoY revenue growth, expanding subscriber base reaching nearly 3 million, and strong long-term potential driven by new specialties like TRT and peptides, alongside AI personalization.

Strong top-line growth and subscriber additions demonstrate healthy underlying business momentum, but investors must monitor operating expenses and legal costs.

Long-term outlook is viewed as very positive, acting as an all-in-one healthcare platform for small-to-medium health problems that bypasses traditional insurance, though caution is advised before earnings due to high volatility.

Mentioned as a comparable stock that is more expensive than Real Brokerage.

Positioned as the clear winner-take-most leader in the telehealth and digital pharmacy space with high projected forward revenue growth and massive scale advantages.

Working through a correction phase that may be nearing its end, with upcoming news announcements regarding peptides suggesting potential re-engagement opportunities.

Acquired a peptide compounding facility and positioned itself for the peptide market, acting as a speculative play on telehealth.

Experienced a price drop due to an FTC lawsuit, but legal proceedings will take years while business catalysts like GLP-1s and international growth remain robust.

Sold off sharply to the $27-$29 range, viewed as an irrational reaction since healthcare subscription services are recession-resistant with strong recurring revenue.

Maintains a strong medium-term trend and is considered a high-beta growth play tied to consumer trends in peptides and alternative health treatments.

Dropped significantly due to disappointment and market skepticism regarding its peptide business expansion.

Increasingly trading based on peptide regulation news and FDA announcements rather than traditional telemedicine fundamentals.